US Stock MarketDetailed Quotes
GRTS Gritstone Bio
- 0.220
- -0.360-62.08%
Close Oct 1 16:00 ET
- 0.211
- -0.009-4.14%
Pre 05:51 ET
25.97MMarket Cap-201P/E (TTM)
0.480High0.211Low32.28MVolume0.451Open0.580Pre Close8.70MTurnover27.96%Turnover RatioLossP/E (Static)118.11MShares3.33052wk High1.17P/B25.38MFloat Cap0.21152wk Low--Dividend TTM115.44MShs Float35.200Historical High--Div YieldTTM46.35%Amplitude0.211Historical Low0.269Avg Price1Lot Size
Gritstone Bio Stock Forum
Sign in to post a comment
5
2
$Gritstone Bio (GRTS.US)$
this stock needs a reverse split ASAP
this stock needs a reverse split ASAP
$Gritstone Bio (GRTS.US)$
Haha, this is very good. If you buy, you can consider trading before the market tomorrow.![]()
Haha, this is very good. If you buy, you can consider trading before the market tomorrow.
1
2
$Gritstone Bio (GRTS.US)$ another shit
1
2
$Gritstone Bio (GRTS.US)$ Reuters· just
Gritstone bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer! Well tolerated with no advers events
Gritstone bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer! Well tolerated with no advers events
2
6
$Gritstone Bio (GRTS.US)$
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
Gritstone bio announced encouraging interim Phase 2 data for GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC).
The study showed a 21% relative risk reduction of progression or death with GRANITE vs. control in all treated...
Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
Gritstone bio announced encouraging interim Phase 2 data for GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC).
The study showed a 21% relative risk reduction of progression or death with GRANITE vs. control in all treated...
1
$Gritstone Bio (GRTS.US)$ to report GRANITE progression free survival (PFS) data Q3 2024.
$Gritstone Bio (GRTS.US)$
spike and down again, volume slowly building up
spike and down again, volume slowly building up
$Gritstone Bio (GRTS.US)$ Gritstone Bio (NASDAQ:GRTS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $1.742 million which beat the analyst consensus estimate of $1.104 million by 57.77 percent. This is a 28.69 percent decrease over sales of $2.443 million the same per...
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
JimboJaggins : Screw it, I'm in.
108S : Lets see…. But I am selling all mine